Effectiveness of Nefopam in Breast Cancer Surgery
Primary Purpose
Breast Neoplasm Malignant Primary
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Nefopam
Normal Saline
Sponsored by
About this trial
This is an interventional supportive care trial for Breast Neoplasm Malignant Primary
Eligibility Criteria
Inclusion Criteria:
- Total mastectomy
- Modified radical mastectomy
- Nipple-sparing mastectomy
- American Society of Anesthesiologists physical status I or II
- Postoperative use of intravenous patient-controlled analgesia
Exclusion Criteria:
- Chronic analgesia medication
- Pregnancy
- Lactating women
- Previous operation history due to breast cancer
- Cooperation with other surgery
- Contraindication of nefopam
Sites / Locations
- Seoul National University Bundang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Control
Nefopam
Arm Description
Placebo use instead of nefopam
Intraoperative use of nefopam 40 mg
Outcomes
Primary Outcome Measures
Change of cumulative analgesia volume infused via intravenous patient-controlled analgesia device
Secondary Outcome Measures
Change of numerical rating scale for postoperative pain
Full Information
NCT ID
NCT02949310
First Posted
October 26, 2016
Last Updated
January 9, 2018
Sponsor
Seoul National University Bundang Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02949310
Brief Title
Effectiveness of Nefopam in Breast Cancer Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (Actual)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Bundang Hospital
4. Oversight
5. Study Description
Brief Summary
Breast cancer surgery is known to cause severe acute postoperative pain, which can persist for a long time. The investigators administered nefopam preventively to patients undergoing total mastectomy or modified radical mastectomy with axillary lymph node dissection or sentinel lymph node biopsy, and evaluated its efficacy on acute and chronic postoperative pain.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasm Malignant Primary
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Placebo use instead of nefopam
Arm Title
Nefopam
Arm Type
Experimental
Arm Description
Intraoperative use of nefopam 40 mg
Intervention Type
Drug
Intervention Name(s)
Nefopam
Intervention Type
Drug
Intervention Name(s)
Normal Saline
Primary Outcome Measure Information:
Title
Change of cumulative analgesia volume infused via intravenous patient-controlled analgesia device
Time Frame
At postoperative 4 hour, 24 hour, 48 hour, 72 hour, 10 day, and 3 month
Secondary Outcome Measure Information:
Title
Change of numerical rating scale for postoperative pain
Time Frame
At postoperative 4 hour, 24 hour, 48 hour, 72 hour, 10 day, and 3 month
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Total mastectomy
Modified radical mastectomy
Nipple-sparing mastectomy
American Society of Anesthesiologists physical status I or II
Postoperative use of intravenous patient-controlled analgesia
Exclusion Criteria:
Chronic analgesia medication
Pregnancy
Lactating women
Previous operation history due to breast cancer
Cooperation with other surgery
Contraindication of nefopam
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Gyeonggi
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hyo-Seok Na
Phone
1087012913
Email
hsknana@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Effectiveness of Nefopam in Breast Cancer Surgery
We'll reach out to this number within 24 hrs